Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etanercept biosimilar - Dong-A ST/Meiji Seika Pharma

Next Previous
Search
Drug Profile

Etanercept biosimilar - Dong-A ST/Meiji Seika Pharma

Alternative Names: DA-3853; DMB-3853

Latest Information Update: 17 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical; Meiji Seika Pharma
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
  • 19 Jun 2015 Etanercept biosimilar - Dong-A ST/Meiji Seika Pharma is available for licensing in World (excluding South Korea and Japan) as of 19 Jun 2015 (Dong A ST Annual Report 2014 Pipeline)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top